Breaking News

Oncology Venture Out-Licenses Clinical Assets to Smerud

Smerud will advance development of LiPlaCis in late stage metastatic breast cancer and 2X-111 in glioblastoma multiforme.

By: Contract Pharma

Contract Pharma Staff

Oncology Venture A/S (OV) has signed a definitive agreement to out-license two clinical assets, LiPlaCis and 2X-111, to Smerud Medical Research International for further clinical and commercial development. OV will receive regulatory milestone fees of nearly $30 million plus royalties on sales for each drug if all milestones are met. OV also terminated its prior license agreement with Cadila Pharmaceuticals for the development of LiPlaCis in India. In September 2019, OV announced a significa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters